Madrigal Pharmaceuticals (MDGL) EBIT (2010 - 2026)
Madrigal Pharmaceuticals (MDGL) reported EBIT of -$92.7 million for Q1 2026, down 16.91% year-over-year from -$111.6 million in Q1 2025, and down 55.55% quarter-over-quarter from -$59.6 million in Q4 2025.
Madrigal Pharmaceuticals (MDGL) EBIT (2010 - 2026) Analysis & Trends
Madrigal Pharmaceuticals (MDGL) has 17 years of EBIT data on file, last reported at -$92.7 million in Q1 2026.
- EBIT for Q1 2026 came in at -$92.7 million, down 16.91% year-over-year; the trailing twelve-month figure through Mar 2026 was -$313.5 million (up 26.26% YoY), and the FY2025 annual result was -$300.1 million, up 39.72% from the prior year.
- EBIT slipped to -$92.7 million in Q1 2026 per MDGL's latest filing, from -$59.6 million in the prior quarter.
- Over five years, EBIT peaked at -$47.2 million in Q2 2025 and troughed at -$162.5 million in Q2 2024.
- A 5-year average of -$92.0 million and a median of -$85.3 million in 2022 frame the typical range for EBIT.
- The sharpest annual moves came in 2024 and 2025: EBIT plunged 94.08% in 2024, then surged 70.96% in 2025.
- A 5-year view of EBIT shows it stood at -$85.3 million in 2022, then slumped by 37.37% to -$117.2 million in 2023, then surged by 42.82% to -$67.0 million in 2024, then rose by 11.03% to -$59.6 million in 2025, then slumped by 55.55% to -$92.7 million in 2026.
- Business Quant data shows MDGL's EBIT at -$92.7 million in Q1 2026, -$59.6 million in Q4 2025, and -$114.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -32.68 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.97 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -19.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.82 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -15.76 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.51 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.14 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -65.83 Mn |
| 10 | Madrigal Pharmaceuticals | 14.67 Bn | 14.44 Bn | - | -92.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -92.72 Mn |
| Dec 31, 2025 | -59.61 Mn |
| Sep 30, 2025 | -113.98 Mn |
| Jun 30, 2025 | -47.20 Mn |
| Mar 31, 2025 | -79.31 Mn |
| Dec 31, 2024 | -67.00 Mn |
| Sep 30, 2024 | -116.30 Mn |
| Jun 30, 2024 | -162.54 Mn |
| Mar 31, 2024 | -152.04 Mn |
| Dec 31, 2023 | -117.18 Mn |
| Sep 30, 2023 | -98.53 Mn |
| Jun 30, 2023 | -86.45 Mn |
| Mar 31, 2023 | -78.34 Mn |
| Dec 31, 2022 | -85.30 Mn |
| Sep 30, 2022 | -80.41 Mn |
| Jun 30, 2022 | -70.27 Mn |
| Mar 31, 2022 | -57.59 Mn |
| Dec 31, 2021 | -64.60 Mn |
| Sep 30, 2021 | -63.16 Mn |
| Jun 30, 2021 | -61.74 Mn |